- Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med 2017;23(7):804–14.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018;18:3–14.
- Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018;392(10160):2180–93.
Perspectives
How does this study impact clinical practice?
- Activating the GLP-1 receptor alone may not substantially reduce fasting insulin levels.
- New agents with dual effects may offer distinct mechanisms of glucose control for people with T2D.
- By both improving beta-cell function and reducing insulin resistance through dual activation of GLP-1 and GIP receptors, tirzepatide potentially confers not only glucose control and weight loss, but also reduction in disease severity and improvement in metabolic health.
